TheStreet's Jim Cramer says investors need to see money come back to high-growth names, which have seen a shrinking price-to-earnings multiple. Celgene has been in a decline but the company could have $15-$16 earnings power in a couple of years, says Cramer, and it is cheaper than Merck and Pfizer. Cramer is also watching Salesforce.com, which has seen a shrinking multiple since it reported a great quarter. If Celgene and Salesforce turn around, money will come back to high-growth from value names.
-- Get Cramer's top stocks with
Action Alerts PLUS
Trade with him FREE for 14-days.